Dysken M W, Javaid J I, Chang S S, Schaffer C, Shahid A, Davis J M
Psychopharmacology (Berl). 1981;73(3):205-10. doi: 10.1007/BF00422403.
We conducted a double-blind study of therapeutic outcome versus mean steady-state levels in 29 newly admitted schizophrenic and schizoaffective patients who were treated with a constant dose of fluphenazine HCI over a 2-week period. both an upper and lower end of the therapeutic window were suggested by three nonresponders whose plasma levels were above 2.8 ng per ml and by two nonresponders and one partial responder whose plasma levels were below 0.2 ng per ml. The mean terminal half-life of fluphenazine (+ or - SD) was 16.4 + or - 13.3 h. We found that concomitant use of benztropn mesylate during the initial 4 weeks of fluphenazine treatment did not significantly alter fluphenazine plasma levels.
我们对29名新入院的精神分裂症和分裂情感性障碍患者进行了一项双盲研究，比较治疗结果与平均稳态水平。这些患者在2周内接受恒定剂量的盐酸氟奋乃静治疗。三名血浆水平高于2.8 ng/ml的无反应者、两名血浆水平低于0.2 ng/ml的无反应者和一名部分反应者提示了治疗窗的上限和下限。氟奋乃静的平均终末半衰期（±标准差）为16.4±13.3小时。我们发现，在氟奋乃静治疗的最初4周内同时使用甲磺酸苯扎托品并没有显著改变氟奋乃静的血浆水平。
